https://european-biotechnology.com/wp-content/uploads/2024/04/Siemens.jpg359640Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-07-27 11:05:332021-07-27 11:05:33AXA IM Alts raises €1.9bn European Life Sciences Fund
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-07-27 10:00:002021-07-27 10:00:00New head for Orbit Discovery
Italian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies.
https://european-biotechnology.com/wp-content/uploads/2024/04/panakes-fabrizio.jpg15552048Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2021-07-22 08:00:002021-07-22 08:00:00Panakès expands into biotech with €150m fund
Mainz-based BioNTech is expanding its portfolio for cancer therapies with theneoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.
https://european-biotechnology.com/wp-content/uploads/2024/04/biontech-20210719.jpg12801920Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-07-20 08:00:002021-07-20 08:00:00BioNTech takes over cancer immunotherapy platform
Dutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers.
https://european-biotechnology.com/wp-content/uploads/2024/04/coins-1726618_1920.jpg12791920Uta Mommert/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngUta Mommert2021-07-15 07:00:002021-07-15 07:00:00€26m financing for ISA Pharmaceuticals
Vaccine development – strategic approach
Sponsored PublicationsThis white paper explores vaccine development during a pandemic, a response to complex challenges that traditional manufacturing methods won’t solve.
Byondis and Glycotope merge platforms to target carbohydrates
Latest NewsCancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement.
Artios Pharma Ltd raises US-$153m Series C financing
Latest NewsCancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline.
AXA IM Alts raises €1.9bn European Life Sciences Fund
Latest NewsAXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector.
New head for Orbit Discovery
AppointmentsDr Neil Butt is the new Chief Executive Officer at Oxford-based Orbit Discovery.
Synaffix inks $246m deal with ProfoundBio
Latest NewsSynaffix has nonexclusivey licensed its award-winning ADC technologies to Chinese ProfoundBio in an up to $246m deal
Panakès expands into biotech with €150m fund
Latest NewsItalian venture capital firm Panakès Partners, previously active in medtech, has closed the €150m purple fund with the goal to invest in underserved European Life Science companies.
BioNTech takes over cancer immunotherapy platform
Latest NewsMainz-based BioNTech is expanding its portfolio for cancer therapies with the neoantigen TCR Cell Therapy R&D pipeline and manufacturing site from Gilead Science subsidiary Kite Pharmaceuticals.
Nanosyrinx raises £6.2m to validate drug delivery platform
Latest NewsCoventry-based NanoSyrinx plc has raised £6.2m in seed financing to develop a new cell engineering tool for novel targeted therapeutic modalities.
€26m financing for ISA Pharmaceuticals
Latest NewsDutch immunotherapy company ISA Pharmaceuticals has closed a €26m funding round that will go towards advancing its therapy targeting HPV16-related cancers.